ReviewThe journal of allergy and clinical immunology. In practice2020
Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection.
Review in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 6 syntheses or guidelines pooled it, 303 citations in OpenAlex.
- Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Pooled it
- Gene variants associated with skin barrier dysfunction in atopic dermatitis: a systematic review and meta-analysis.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025Pooled it
- Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis.Frontiers in pediatrics · 2022Pooled it
- Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- Are behavioral interventions a better choice for atopic dermatitis patients? A meta-analysis of 6 randomized controlled trials.Anais brasileiros de dermatologiaPooled it
- Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.Paediatric drugs · 2025Trial
- Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale.Journal of patient-reported outcomes · 2024Trial
- Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study.Dermatology and therapy · 2026Article
- Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial Influences.Current allergy and asthma reports · 2026Review
- Artificial intelligence in atopic dermatitis: Current applications and future perspectives.Chinese medical journal · 2026Review
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.Italian journal of pediatrics · 2026Article
- Psychometric Evaluation of Worst Pruritus Numeric Rating Scale in Adults With Moderate-to-Severe Atopic Dermatitis.Dermatology and therapy · 2026Article
- Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis.Dermatology and therapy · 2026Article
- Development of a clinical indicator-based severity scoring system for pediatric atopic dermatitis and evaluation of dupilumab treatment outcomes.American journal of translational research · 2026Article
- Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan.Japanese journal of ophthalmology · 2026Review
- Repurposing Old Drugs: Roflumilast as a Promising Therapeutic Option for Plaque Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Review
- Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.Dermatology and therapy · 2026Article
- Effects of topicalFrontiers in medicine · 2026Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting children and adults. The intense pruritus and rash can be debilitating, significantly impairing quality of life. Until recently, treatment was largely nonspecific and, in severe disease, sometimes ineffective and/or fraught with many side effects. Now, multiple agents targeting specific disease pathways are available or in development. Two new therapies, crisaborole and dupilumab, have become available since 2016, and dupilumab has dramatically improved outcomes for adults with severe AD. This article provides an overview of AD, including strategies for differential diagnosis and assessment of disease severity to guide treatment selection. Key clinical trials for crisaborole and dupilumab are reviewed, and other targeted treatments now in development are summarized. Two cases, representing childhood-onset and adult-onset AD, are discussed to provide clinical context for diagnosis, severity assessment, and treatment selection and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.